Drug intelligence / Profile preview

fugliflozin

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Fugliflozin (SHR2258) is an orally active small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2), developed by Jiangsu Hengrui Pharmaceuticals for the treatment of type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal tubules of the kidney, fugliflozin reduces renal glucose reabsorption and increases urinary glucose excretion, thereby lowering blood glucose levels in an insulin-independent manner. It is part of Hengrui's pipeline of metabolic disease treatments, alongside their approved SGLT2 inhibitor henagliflozin. Fugliflozin is chemically distinct from other gliflozins, featuring a fluorinated structure designed to optimize its pharmacokinetic and pharmacodynamic profile.

Other names: fugliflozin

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on fugliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fugliflozin.

Explore the full profile